Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
4
ESG
Strong progress on ESG in Q2, with focus on new health equity
initiatives and advancing our Global Health efforts
Leading on
health equity
> New target on
clinical trial diversity
Embedding diversity &
inclusion in 100% of Ph3
studies with US participation
> Pledged 10-year
commitment1
USD 20m to empower 1200
African American students,
USD 13.7m to establish
research centers
> Addressing unmet need
in breast cancer
Multiyear commitment to address
racial disparities in breast cancer:
estimated at USD 93bn in excess
medical care costs in US
Advancing our
patient reach
> Malaria milestone
1bn courses of
antimalarial treatment
delivered since 1999
> Accelerate use of digital technologies for global health
First use case for dengue which affects 400m cases / year
Developing disease surveillance solution with HP Enterprises
1. Via the Novartis US Foundation in collaboration with Historically Black Colleges, Universities, other organization and companies.
17 Investor Relations | Q2 2021 Results
1 NOVARTIS | Reimagining MedicineView entire presentation